Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 22


An in silico approach helped to identify the best experimental design, population, and outcome for future randomized clinical trials.

Bajard A, Chabaud S, Cornu C, Castellan AC, Malik S, Kurbatova P, Volpert V, Eymard N, Kassai B, Nony P; CRESim & Epi-CRESim study groups.

J Clin Epidemiol. 2015 Jul 15. pii: S0895-4356(15)00338-8. doi: 10.1016/j.jclinepi.2015.06.024. [Epub ahead of print]


A methodological framework for drug development in rare diseases.

Nony P, Kurbatova P, Bajard A, Malik S, Castellan C, Chabaud S, Volpert V, Eymard N, Kassai B, Cornu C; CRESim; Epi-CRESim.

Orphanet J Rare Dis. 2014 Nov 18;9:164. doi: 10.1186/s13023-014-0164-y.


Experimental designs for small randomised clinical trials: an algorithm for choice.

Cornu C, Kassai B, Fisch R, Chiron C, Alberti C, Guerrini R, Rosati A, Pons G, Tiddens H, Chabaud S, Caudri D, Ballot C, Kurbatova P, Castellan AC, Bajard A, Nony P; CRESim & Epi-CRESim Project Groups, Aarons L, Bajard A, Ballot C, Bertrand Y, Bretz F, Caudri D, Castellan C, Chabaud S, Cornu C, Dufour F, Dunger-Baldauf C, Dupont JM, Fisch R, Guerrini R, Jullien V, Kassaï B, Nony P, Ogungbenro K, Pérol D, Pons G, Tiddens H, Rosati A, Alberti C, Chiron C, Kurbatova P, Nabbout R.

Orphanet J Rare Dis. 2013 Mar 25;8:48. doi: 10.1186/1750-1172-8-48. Review.


Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome.

Trédan O, Manuel M, Clapisson G, Bachelot T, Chabaud S, Bardin-dit-Courageot C, Rigal C, Biota C, Bajard A, Pasqual N, Blay JY, Caux C, Ménétrier-Caux C.

Eur J Cancer. 2013 May;49(7):1673-82. doi: 10.1016/j.ejca.2012.11.028. Epub 2012 Dec 19.


Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial.

Pérol D, Provençal J, Hardy-Bessard AC, Coeffic D, Jacquin JP, Agostini C, Bachelot T, Guastalla JP, Pivot X, Martin JP, Bajard A, Ray-Coquard I.

BMC Cancer. 2012 Dec 17;12:603. doi: 10.1186/1471-2407-12-603.


[Prostate-specific antigen bounce after permanent seed prostate brachytherapy: a literature review].

Mazeron R, Bajard A, Pommier P.

Cancer Radiother. 2012 Dec;16(8):702-10; quiz 722, 725. doi: 10.1016/j.canrad.2012.09.004. Epub 2012 Nov 22. Review. French.


Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression.

Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, Renaudineau S, Poyet G, Labidi-Galy SI, Goddard-Leon S, Durand I, Le Mercier I, Bajard A, Bachelot T, Puisieux A, Puisieux I, Blay JY, Ménétrier-Caux C, Caux C, Bendriss-Vermare N.

Cancer Res. 2012 Oct 15;72(20):5188-97. doi: 10.1158/0008-5472.CAN-11-3468. Epub 2012 Jul 25.


[Regional recurrence of triple-negative breast cancer: interest of systematic adjuvant lymph node irradiation?].

Clerc J, Sunyach MP, Duruisseaux M, Mignotte H, Bajard A, Tredan O, Arnaud A.

Gynecol Obstet Fertil. 2013 Feb;41(2):90-5. doi: 10.1016/j.gyobfe.2012.05.002. Epub 2012 Jul 4. French.


Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence.

Mazeron R, Bajard A, Montbarbon X, Gassa F, Malet C, Rocher F, Clippe S, Bringeon G, Desmettre O, Pommier P.

Radiat Oncol. 2012 Mar 26;7:46. doi: 10.1186/1748-717X-7-46.


Deep sedation in pediatric imaging: efficacy and safety of intravenous chlorpromazine.

Heng Vong C, Bajard A, Thiesse P, Bouffet E, Seban H, Marec Bérard P.

Pediatr Radiol. 2012 May;42(5):552-61. doi: 10.1007/s00247-011-2310-1. Epub 2012 Jan 13.


Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.

Asmane I, Kurtz JE, Bajard A, Guastalla JP, Meeus P, Tredan O, Labidi Galy I, Moullet I, Ardisson P, Vincent L, Coeffic D, Dufresne A, Bergerat JP, Ray-Coquard I.

Bull Cancer. 2011 Oct;98(9):80-9. doi: 10.1684/bdc.2011.1436.


Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer.

Bachelot T, Bajard A, Ray-Coquard I, Provencal J, Coeffic D, Agostini C, Boisseau M, Kaphan R, Dramais D, Oprea C, Ferri-Dessens RM, Guastalla JP, Perol D.

Oncology. 2011;80(3-4):262-8. doi: 10.1159/000329066. Epub 2011 Jul 6.


Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer.

Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, Combes JD, Faget J, Mithieux F, Cassignol A, Tredan O, Durand I, Ménétrier-Caux C, Caux C, Blay JY, Ray-Coquard I, Bendriss-Vermare N.

Cancer Res. 2011 Aug 15;71(16):5423-34. doi: 10.1158/0008-5472.CAN-11-0367. Epub 2011 Jun 22.


Validation of prognostic scores for survival in cancer patients beyond first-line therapy.

Trédan O, Ray-Coquard I, Chvetzoff G, Rebattu P, Bajard A, Chabaud S, Pérol D, Saba C, Quiblier F, Blay JY, Bachelot T.

BMC Cancer. 2011 Mar 15;11:95. doi: 10.1186/1471-2407-11-95.


Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer.

Belbaraka R, Trédan O, Ray-Coquard I, Chvetzoff G, Bajard A, Pérol D, Ismaili N, Ismaili M, Errihani H, Bachelot T, Rebattu P.

BMC Res Notes. 2010 Jun 10;3:164. doi: 10.1186/1756-0500-3-164.


Body weight change in women receiving adjuvant chemotherapy for breast cancer: a French prospective study.

Trédan O, Bajard A, Meunier A, Roux P, Fiorletta I, Gargi T, Bachelot T, Guastalla JP, Lallemand Y, Faure C, Pérol D, Bachmann P.

Clin Nutr. 2010 Apr;29(2):187-91. doi: 10.1016/j.clnu.2009.08.003. Epub 2009 Aug 26.


Revisiting the level of evidence in randomized controlled clinical trials: A simulation approach.

Bajard A, Chabaud S, Pérol D, Boissel JP, Nony P.

Contemp Clin Trials. 2009 Sep;30(5):400-10. doi: 10.1016/j.cct.2009.06.005. Epub 2009 Jul 1.


Outcome of recurrent and metastatic small cell carcinoma of the bladder.

Ismaili N, Heudel PE, Elkarak F, Kaikani W, Bajard A, Ismaili M, Errihani H, Droz JP, Flechon A.

BMC Urol. 2009 Jun 6;9:4. doi: 10.1186/1471-2490-9-4.


A candidate molecular signature associated with tamoxifen failure in primary breast cancer.

Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.

Breast Cancer Res. 2008;10(5):R88. doi: 10.1186/bcr2158. Epub 2008 Oct 17.


Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma.

Bajard A, Westeel V, Dubiez A, Jacoulet P, Pernet D, Dalphin JC, Depierre A.

Lung Cancer. 2004 Sep;45(3):317-23.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk